In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
The Drug Hunter’s Assistant: Accelerating Drug Discovery With AI
An article featuring commentary by Andrew Garrett, discussing the importance of navigating through the hype surrounding AI and the ways in which the Pharma industry can manage expectations.
-
The Danger of 'Going too far' with AI
Andrew Garrett spoke on a panel at the Financial Times Pharmaceutical & Biotechnology conference, about the recent integration of artificial intelligence (AI) enabled services in pharma R&D.
-
-
Validating Value Data: AI & Outcomes
The application of AI and machine learning in establishing a treatment’s value proposition is still a relatively new concept in pharma. Katya Svoboda, Taneesha Chawla, and Tanvi Ahuja, authors of the ICON whitepaper, The Impact of Artificial Intelligence on Outcomes Based Contracting discuss the challenges and opportunities in the October 2019
-
Can Digital Technologies and AI improve R&D productivity enough to restore ROI?
A thought leadership article authored by Tom O’Leary, exploring what can be done to help ensure return on investment in clinical trials.
-
Hasta la vista, maybe? Terminating the Hollywood view of AI in pharma
In drug development, the success of AI depends on gathering the right data and being able to prove its authenticity when an application is subject to regulatory scrutiny. Read this Pharmaceutical Market Europe (PME) article to explore featured commentary from ICON expert Tom O’Leary on the use of AI in the pharmaceutical sector.
-
The Digital Trial: How Technology Is Changing Trial Design, Start-Up And Close-Out
The constant data stream from patients’ mobile devices and sensors generate large datasets that are difficult to analyze manually—just one motion sensor gathering data from a few dozen patients creates nearly one billion data points per day (ICON). To understand these large datasets, AI and machine learning are necessary to automate analyses. Incorporating this technology can lead to faster and more transparent access to data. In addition, it can help sponsors collect the right data to support submission and filing for regulatory review, and, in the end, speed a product’s path to approval and reduce time to market. In this Clinical Informatics News article, featuring commentary from ICON expert Marie McCarthy, leveraging technology to accelerate study close-out is further discussed.
-
A New Horizon
A PharmaTimes article featuring commentary from Tom O’Leary on the future of AI in healthcare. O’Leary discusses how the key to maximising AI’s involvement in pharma development is to utilise its ability to draw distinctions and correlations, which would otherwise elude human observation. However, also notes the potential for AI is most exciting when paired with human experience, creativity and instinct.
